Author’s response to reviews

Title: A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: The Heidelberg REMOTUX trial

Authors:

Anne K Berger (anne.berger@med.uni-heidelberg.de)
Carl von Gall (c.vgall@me.com)
Ulrich Abel (ulrich.abel@nct-heidelberg.de)
Stefan Delorme (s.delorme@dkfz-heidelberg.de)
Matthias Kloor (matthias.kloor@med.uni-heidelberg.de)
Jennifer Ose (jennifer.ose@med.uni-heidelberg.de)
Tim F Weber (tim.weber@med.uni-heidelberg.de)
Annika Stange (annika.stange@med.uni-heidelberg.de)
Georg M Haag (georgmartin.haag@med.uni-heidelberg.de)
Uwe Haberkorn (uwe.haberkorn@med.uni-heidelberg.de)
Florian Lordick (medklinik3@klinikum-braunschweig.de)
Dirk Jäger (dirk.jaeger@med.uni-heidelberg.de)

Version: 2 Date: 2 February 2012

Author’s response to reviews:

Dear editorial board,

according to Tonilynn Manibo’s email from Jan 25th please find attached the ethical approvals of the REMOTUX trial. Additionally, there have been corrections concerning the "competing interests" section of the manuscript. The corrections are as follows:

"The authors state that this study is an investigator-initiated trial, funded by Merck Pharma GmbH. The contract between the financial sponsor and the University of Heidelberg leaves the full responsibility for the scientific work, the management of data, and for analysis and publication to the investigators"

I confirm that there are no other manuscripts that are under submission with other journals based on this study protocol.

Sincerely yours,

Anne Berger